Per the Frontiers Media S.A. 2023 report, progress in the field of induced pluripotent stem cells (iPSCs) has opened a new gateway for research in therapeutics. iPSCs are mainly intended for research and clinical studies such as disease modeling, regenerative medicine, and drug discovery/drug cytotoxicity studies. For example, iPSCs can be used to convert differentiated somatic cells to multipotent stem cells to generate different cell types of adult tissues. Thus, iPSCs have shown promising results in regenerative medicine, particularly for replacing diseased or injured cells. iPSCs are widely used to regenerate tissue-specific cells for transplantation in patients for treating injuries and degenerative diseases. Studies such as drug discovery involving screening of small molecules and toxicity testing for safety assessment have been successfully disclosed positive iPSCs-based results. The aforementioned factors are expected to offer lucrative growth opportunities to companies in the stem cell therapy market in the coming years.
Asia Pacific stem cell therapy market is analyzed based on the five major countries such as China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The Asia Pacific region is expected to be the fastest-growing region among all other regions. The growth of the market in the Asia Pacific region is expected to grow at a faster pace owing to factors such as increasing need for superior treatment solutions, favorable regulatory scenarios, increasing focus on research and development activities, and growing awareness regarding benefits offered by stem cell therapy. Additionally, developing healthcare infrastructure and increasing investments in order to boost the research activities are projected to drive the Asia Pacific stem cell therapy market during the forecast period.
The Asia Pacific stem cell therapy market is segmented into type, treatment, application, end user, and country.
The Asia Pacific stem cell therapy market, by type, is segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and other stem cell therapy. The adult stem cell therapy segment held the largest market share in 2022.
Based on treatment, the Asia Pacific stem cell therapy market is bifurcated into allogeneic and autologous. The allogenic segment held the largest share of the market in 2022.
Based on application, the Asia Pacific stem cell therapy market is divided into musculoskeletal, dermatology, cardiology, drug discovery and development, other applications. The musculoskeletal segment held the largest share of the market in 2022.
The Asia Pacific stem cell therapy market, by end user, is segmented into academic & research institutes and hospitals & clinics. The academic & research institutes segment held the largest share of the market in 2022.
Based on country, the Asia Pacific stem cell therapy market is segmented into Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. Germany dominated the market in 2022.
MEDIPOST; Mesoblast Limited; TiGenix NV; JCR Pharmaceuticals Co. Ltd.; and NuVasive Inc are the leading companies operating in the Asia Pacific stem cell therapy market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 403.94 Million |
| Market Size by 2028 | US$ 1,180.20 Million |
| CAGR (2022 - 2028) | 19.6% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Stem Cell Therapy Market is valued at US$ 403.94 Million in 2022, it is projected to reach US$ 1,180.20 Million by 2028.
As per our report Asia Pacific Stem Cell Therapy Market, the market size is valued at US$ 403.94 Million in 2022, projecting it to reach US$ 1,180.20 Million by 2028. This translates to a CAGR of approximately 19.6% during the forecast period.
The Asia Pacific Stem Cell Therapy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Stem Cell Therapy Market report:
The Asia Pacific Stem Cell Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Stem Cell Therapy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Stem Cell Therapy Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Stem Cell Therapy Market
